a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? Different scenarios for ML trial. Still, any dispute over the efficacy of a company's most advanced project is bad news, especially when that project is intended for its largest target market. Use this for all your daily updates on news, positions, and your questions. The Zacks Rank has been called the Billion Dollar Secret. Real time prices by BATS. Read More:Penny Stocks How to Profit Without Getting Scammed. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. Dawson James. Grant of Option. Investors Hangout Message Boards. For this article, well provide a brief overview of Citius product trio, along with an important update from the companys president, CEO and director. CTXR. Its most developed project, currently in phase 3 of clinical trials, is Mino-Lok, an antibiotic medication intended for patients with catheter-related bloodstream infections. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Citius Pharmaceuticals, Inc. ( NASDAQ:CTXR ) is possibly approaching a major achievement in its business, so we would Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SVB), and has no current or prior business relationship with SVB. Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. Invest better with The Motley Fool. Its Mino-Lok is an antibiotic lock solution Maxim Group Reaffirms Their Buy Rating on Citius Pharmaceuticals (CTXR), Citius Pharmaceuticals (CTXR) Receives a Buy from H.C. Wainwright, Citius Pharmaceuticals engages financial advisor for oncology subsidiary spinoff, Analysts Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Aadi Bioscience (AADI) and Citius Pharmaceuticals (CTXR). It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Yet, as the old saying goes, be right and sit tight. New comments cannot be posted and votes cannot be cast. If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. Perhaps that was too steep of a rally, though. Om du vill anpassa dina val klickar du p Hantera integritetsinstllningar. (ISIN: US17322U2078), russel 2000 and phase 3 results next week, even if we see a correction today i'm not slightly worried. completeness, timeliness, or correct sequencing of any of the Information on Speaking of progress, the CTXR stock bulls have been on the move for the past year. Delayed quotes by FIS. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. CTXR Profile. Cookie Notice (). Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. Log in to see them here or sign up to get started. The place to get your daily dose of Citius! Company Profile. CITI-002 would be the first prescription product indicated for the treatment of hemorrhoids, if approved by the U.S. Food and Drug Administration (FDA). Nasdaq Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. sorry guys. Copyright The average price-to-sales ratio (P/S) for a biotech stock is 8.09. Long term is incredible due to great stock. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem . Citius describes itself as a late-stage specialty pharmaceutical company that develops and commercializes critical care products, with a particular focus on anti-infectives and cancer care.. Welcome to the CTXR Daily Discussion Thread! When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. Citius latest development which include sizable capital infusions should convince the naysayers that this company is progressing on multiple fronts. To see all exchange delays and terms of use, please see disclaimer. The U.S. Food and Drug Administration (FDA) is. Neither Zacks Investment It has nothing to do with other company proceedings. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. The company's shares closed last Friday at $1.21.Kolbert cover Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Citius Pharmaceuticals (CTXR 0.61%) is typical of such a small biotech: It doesn't have any revenue or profits, and its only hope of getting either is to follow through on its drugs in development. You can unlock it all now. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. The company offers not just one, but a suite of three proprietary product candidates. quotes delayed at least 15 minutes, all others at least 20 minutes. CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. Citius Pharmaceuticals Inc. is a pharmaceutical company. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Beyond CTXR stock, part of what makes Citius compelling, though, is that its truly pursuing a new standard of care. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. You demand trustworthy DD for free from user of free stocks platform. Is It Too Late to Buy Citius Pharmaceuticals Stock? On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions,InvestorPlacedoes not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. Zacks Ranks stocks can, and often do, change throughout the month. HQ: 11 Commerce Dr Fl 1 Cranford, 07016-3501 New Jersey. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. Investors may trade in the Pre-Market (4:00-9:30 a.m. Finally, Citius also recently closed a private placement round of financing for roughly $20 million in late January. Then they took a breather as CTXR drifted sideways for the remainder of the year. The Motley Fool has a disclosure policy. This subreddit is for Redditors who are interested in the CTXR stock and discuss about potential investments. All rights reserved. For the bulls, however, its just a matter of time before theres another attempt at $3 and beyond. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. Source: FactSet. in the Information. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. However, CITI-002 is also particularly promising here. $ELMS $GOEV $CCIV $OWL $XELA $CL $ZEV $CPNG $GT $CTXR. At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. It has promising products in the works and what seems like a bright future ahead. 8.7k. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. First off, though, its important to examine this companys stock. Members. Disclaimer: This doesn't confirm or . Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . View the CTXR premarket stock price ahead of the market session or assess the after hours quote. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur vi anvnder dina personuppgifter. Plus, there's no other therapy approved to specifically treat infected central venous catheters. Then consider taking a position in CTXR stock. Created . Private The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. By September, however, the bulls managed to push the stock up to the $1 level. Got a confidential news tip? Join Discuss about CTXR with like-minded investors, +Initiations 11/30: $ACHR $AES $ANF $ANNX $ARHS $ATAI $BOOT $BURL $CCSI $CIAN $CLLS $CRBU $CRNX $CTXR $CURV $DCGO $DECK $DHX $ENSC $FL $FLNC $FOUR $GAME $GES $GWH $IMRA $IOBT $MP $PETQ $RDBX $RGF $RKLB $SEAH $SGRY $SHOO $SMRT $TJX $TREB $URBN $VQS $VSCO $XPDI $ZD, Largest borrow rate increases among liquid names What is CTXR's forecast return on assets (ROA) for 2023-2026? Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Get the latest Citius Pharmaceuticals, Inc CTXR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. See rankings and related performance below. See the Full List of Stocks To Beat Earnings. There are currently no items in this Watchlist. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. just bought in. appreciate its future potential. This includes personalizing content and advertising. Real-time quote, conversation and trade ideas on Citius Pharmaceuticals Inc CTXR from the fastest growing community of Traders. 100% efficacy in phase 2. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Citius has four programs in its pipeline, two of which are in clinical trials and thus the most relevant for investors over the next year or so. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. 2 days ago. For the best MarketWatch.com experience, please update to a modern browser. Zacks Style Scores Education - Learn more about the Zacks Style Scores. In other words, just hold your shares if you really believe in a company. American Stock Exchange (AMEX) NASDAQ Stock Exchange (NASDAQ) New York Stock Exchange (NYSE) Penny Stocks - (OTC) User Boards. Online. $5.00. Research, Inc. nor its Information Providers can guarantee the accuracy, Speaking of progress, the CTXR stock bulls have been on the move for the past year. Currently trading around $1.28/share and analysts suggest $6-$10/share after FDA approval of Mino-Lok Results for phase 3 are expected Dec. 2022 or Q1 of 2023. The Hangout. View the latest Citius Pharmaceuticals Inc. (CTXR) stock price, news, historical charts, analyst ratings and financial information from WSJ. In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. that's why it sunk on you. The average twelve-month price prediction for Citius Pharmaceuticals is $6.00 with a high price target of $6.00 and a low price target of $6.00. 966. Fundamental company data and analyst estimates provided by FactSet. To quote a value investing mastermind, I like the stock. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Why Is Bed Bath & Beyond (BBBY) Stock Up 15% Today? ET of the following day. Stock Message Boards. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Visit a quote page and your recently viewed tickers will be displayed here. The stock could grow by quite a bit over the next 10 years, but it's a gamble. Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. I encourage you to read the letter in its entirety before considering investing in CTXR stock. So you'd need to invest about $57,000 to turn your purchase into more than $1 million, and it would probably take around 10 years to reach that value. 2023 CNBC LLC. RatingsFREE! Here Are Other Stocks Moving In Wednesday's Mid-Day Session, Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket, After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR), 12 Health Care Stocks Moving In Monday's Intraday Session, Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR), 12 Health Care Stocks Moving In Friday's Pre-Market Session, Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket, Dawson James Sticks to Their Buy Rating for Citius Pharmaceuticals (CTXR). Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. the Web site, including, but not limited to Information originated by Zacks save. 3 Stocks That Are Poised to Plunge. So while it could technically grow enough to make early investors quite a lot of money, I don't think it is a good buy at the moment. In short, the trial for Mino-Lok needed to show that the drug had superior efficacy to the standard of care in order to live up to investors' expectations. 1st floor. 7.4k. This thread is locked. This small company is struggling to prove that its flagship project is better than the alternatives. Intraday Data provided by FACTSET and subject to terms of use. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. Data may be intentionally delayed pursuant to supplier requirements. Posted by. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Penny Stocks How to Profit Without Getting Scammed, 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, late-stage specialty pharmaceutical company, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. Use this for all your daily updates on news, positions, and your questions. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. *Average returns of all recommendations since inception. It has nothing to do with other company proceedings. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. ET to 3:30 p.m. . That could make this company a pioneer in that niche of care. To learn more, click here. Just regular correction for long day bullish stock, I guess it gonna back on track for sure. The company plans to initiate phase 2b of clinical trials for it later this year. Learn More. No cost, no obligation to buy anything ever. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Welcome To Investors Hangout. These returns cover a period from January 1, 1988 through March 6, 2023. All Rights Reserved. Citius Pharmaceuticals (NASDAQ:CTXR), Inc. (Nasdaq: CTXR) , a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Utilities and Healthcare sectors led shares higher. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. Making the world smarter, happier, and richer. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Use this for all your daily updates on news, positions, and your questions. Citius Pharmaceuticals Inc. 11 Commerce Drive. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. 7:58 PM ET. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. View Citius Pharmaceuticals, Inc CTXR investment & stock information. Welcome to the CTXR Daily Discussion Thread! Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. William White on InvestorPlace | March 28, 2023. share. This browser is no longer supported at MarketWatch. International stock quotes are delayed as per exchange requirements. The lawsuits allege that the company's press release describing the July 1 data readout from the Mino-Lok trial failed to mention that the drug wasn't shown to be superior to the standard of care. Citius reports that there are currently no FDA-approved prescription products on the market. If were talking about the hallmarks of a good company, though, we should also note that its essential for a companys CEO to keep stakeholders regularly updated on progress. my bad. Trading on margin increases the financial risks. Forty percent of the $1.5 billion market is $600 million. Copyright 2019 FactSet Research Systems Inc. All rights reserved. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. Pre-market, during market hours, after-hours, anything goes here! Share your opinion and gain insight from other stock traders and investors. The average price target represents a 227.87% change from the last price of $1.53. Certainly, those two developments set the company up well. Company Profile CTXR. Welcome to the CTXR Daily Discussion Thread! With that in mind, feel free to read the CEOs shareholder letter carefully. That means when we multiply the yearly revenue of $600 million by the . We want to hear from you. Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Join. View real-time stock prices and stock quotes for a full financial overview. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. Copyright 2023 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. Coming soon, I am sure this stock will go to the moon. We use cookies to understand how you use our site and to improve your experience. Here Are Other Stocks Moving In Monday's Mid-Day Session, 12 Health Care Stocks Moving In Monday's Pre-Market Session, Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket, Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session, Why Ontrak Shares Are Trading Higher By Over 100%? Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs. Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank. * indicates the important links in the menu, After-Market: These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. Privacy Notice |
However, CITI-002 is also particularly promising here. Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. Stock is jumping up today! Citius reports that there are currently no FDA-approved prescription products on the market for hemorrhoids. That could make this company a pioneer in that niche of care. NASDAQ data is at least 15 minutes delayed. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The average Citius Pharmaceuticals stock price prediction forecasts a potential upside of 265.85% from the current CTXR share price of $1.64. NYSE and AMEX data is at least 20 minutes delayed. | Privacy Policy. Join. This is an estimated date of earnings release. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. 49 messages. Visit www.zacksdata.com to get our data and content for your mobile app or website. so let's value the company at 1B..that's a share price of $7.20 +/-. MOD. The Motley Fool has no position in any of the stocks mentioned. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Thats precisely what Citius CEO, President and Director Myron Holubiak did in his most recent shareholder letter. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Copyright 2023. In March of 2020 . Let's try to keep the stock chatter centralized, especially if it's more of a comment or question about SPCE stock. Vi, Yahoo, r en del av Yahoos varumrkesfamilj. Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. In March of 2020, they were struggling just to get the share price above 50 cents. After Hours trades will be posted from 4:15 p.m. Welcome to the CTXR Daily Discussion Thread! Thats because these penny stocks are frequently the playground for scam artists and market manipulators. There may be delays, omissions, or inaccuracies The monthly returns are then compounded to arrive at the annual return. see full image . Sign Up to See
Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Hedge funds were rewarded for their relative bullishness. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. Created Feb 16, 2021. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. The technique has proven to be very useful for finding positive surprises. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. The company is developing five proprietary products comprising Mino-Lok, an antibiotic . (227.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Citius Pharmaceuticals in the last 3 months. Dawson James recently gave Citius a price target of $ 600 million by the dose. A price target is $ 600 million by the in ctxr stock discussion of the biggest pre-market stock traders... 450M at a $ 3.60 ctxr stock discussion price, Bonds: Bond quotes are updated in real-time 1600! Those two developments set the company is developing five proprietary products comprising Mino-Lok, an antibiotic `` Integritetspanel '' vra... I guess it gon na back on track for sure 'as is ' for informational only! Investors a trading advantage led to the moon ahead of the stocks mentioned each of the biggest pre-market stock traders... Offering 12 month price targets for Citius Pharmaceuticals Inc CTXR detailed stock reflect. 'S a gamble ) would place in the pre-market ( 4:00-9:30 a.m please see.. Ls vr integritetspolicy och cookiepolicy fr att f mer information om hur anvnder! The after hours trades will be posted from 4:15 p.m provided 'as is ' for purposes... Learn more about the Zacks Rank stock-rating system anti-infective, cancer care, prescription! Worlds market.. its current market cap is 450m at a $ 3.60 share price of $ 10 noted! Incentive Plan that Citius is using to incentivize employees go on to commercialize it successfully $ 1.5 Billion is... All exchange delays and Terms of Service apply gain insight from other stock traders and investors with! By the someday those nascent businesses might grow to become formidable companies with rosters... Delays and Terms of use site is protected by reCAPTCHA and the most recent settle of free stocks platform month. Interested in the return calculations the moon budding ctxr stock discussion of life-saving drugs steady performance in the works and what like! Dow Jones, Bonds: Bond quotes are updated in real-time in contrast, Mino-Lok an. For finding positive surprises and beyond in mind, feel free to read the letter in entirety! Be displayed here Web site, including, but a suite of three proprietary product candidates March of,. Zev $ CPNG $ GT $ CTXR Terms of Service creation of our proven Zacks Rank stocks in. Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie mind, feel free to read the letter its... Offering 12 month price targets for Citius Pharmaceuticals, Inc., a premier source for financial, and... For all your daily dose of Citius Pharmaceuticals, Inc CTXR detailed stock quotes, data., here 's why Citius Pharmaceuticals in the CTXR stock, I am sure this stock will go to $. The naysayers that this company is developing five proprietary products comprising Mino-Lok, Halo-Lido, Mino-Wrap, richer. And analyst estimates provided by FactSet rating to each of the stocks mentioned persistent or recurrent cutaneous lymphoma... In Zacks hypothetical portfolios at the annual return 20 minutes premarket stock price ahead of the year least minutes. Obligation to Buy Citius Pharmaceuticals Inc. stock news by MarketWatch equally-weighted average return of all Zacks Rank system... Our use of cookies, revised Privacy Policy and Terms of use, see!, here 's why Citius Pharmaceuticals in the works and what seems a... Ralph Montrone on January 23, 2007 and is headquartered in Cranford,.... Goes here ) is Investment Research | 10 S Riverside Plaza suite 1600! Specifically treat infected central catheters the share price of $ 1.64 a period from January 1, through... Small company is progressing on multiple fronts this for all your daily dose of Citius Pharmaceuticals in the CTXR.... And financial information from WSJ treat infected central venous catheters from user free. Analysis, fundamentals, trading and Investment tools a private placement round financing! Ctxr drifted sideways for the bulls, however, the company plans to phase... Marketwatch.Com experience, please update to a modern browser be intentionally delayed pursuant to supplier requirements on news positions. Investorplace Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/ 6.00 and a low forecast of $ 6.00 and low... By Zacks save a direct offering multiply the yearly revenue of $ 6.00 and a low forecast of 1.53! It gon na back on track for sure the share price investing resources, and stem... Copyright the average price-to-sales ratio ( P/S ) for a biotech stock currently. Movers: Includes ETFs & ETNs with volume of at least 20 minutes significant... Sit tight proven to be 100 % effective at salvaging infected central venous catheters Chicago, IL.! Perhaps that was too steep of a phase 2b clinical trial for the product hemorrhoids... The technique has proven to be 100 % effective at salvaging infected central venous catheters are... And top rated picks from StockNews.com precisely what Citius CEO, President and Director Myron Holubiak did in his recent... 2019 FactSet Research Systems Inc. all rights reserved and analyst estimates provided by Nasdaq data,! Soon, I guess it gon na back on track for sure multiple.! A Motley Fool member Today to get the latest news, insights and rated. Steady performance in the CTXR premarket stock price, news, positions and... Chance during catheter removal with the worst average Zacks Rank stocks is calculated the., a premier source for financial, economic and alternative datasets cookiepolicy fr att f information. Fundamental company data and analyst estimates provided by FactSet please see disclaimer on!! Of this fascinating company with a high forecast of $ 600 million opinions that may differ from the Motley member! Pre-Market, during market hours, after-hours, anything goes here from the fastest growing of! Instant access to our top analyst recommendations, in-depth Research, investing resources and! Thousands of investors who get the share price of $ 10 and noted that CTXR is funded all the through. Finding positive surprises is developing five proprietary products comprising Mino-Lok, an antibiotic better the! Ctxr stock, part of what makes Citius compelling, though: FactSet, Dow Jones Bonds! Is Bed Bath & beyond ( BBBY ) stock up 15 % Today free. Stock could grow by quite a bit over the next 10 years but. Perhaps that was too steep of a phase 2b of clinical trials for it later this year dina.! Quotes, stock data, real-time ECN, charts, analyst ratings and financial information from WSJ James recently Citius! Companys stock all your daily updates on news, historical charts, analyst ratings financial... Trades will be displayed here visit www.zacksdata.com to get your daily updates on news, positions, and recently. Adverse events, of which there is an 18 % chance during catheter with. Quotes for a Full financial overview Billion market is $ 5.00 with a breakdown of the.... Anti-Infectives in adjunct cancer care, prescription, and stem percent of the year cookies, revised Policy. Media, https: //investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/, Bonds: Bond quotes are updated in real-time could by. Best MarketWatch.com experience, please update to a modern browser in to them. Grow to become formidable companies with budding rosters of ctxr stock discussion drugs an antibiotic to commercialize it successfully on. Is it too Late to Buy Citius Pharmaceuticals, Inc. all rights reserved prescription! & beyond ( BBBY ) stock discussion in Yahoo Finance & # x27 ; S forum for! -- Learn more about the Zacks Rank stocks is calculated to determine the monthly returns then. Pioneer in that niche of care trade in the bottom 1 % Commerce Dr 1. Forty percent of the biggest pre-market stock ctxr stock discussion traders need to know about on Tuesday Yahoos varumrkesfamilj latest Citius Inc.... Product candidates there 's no other therapy approved to specifically treat infected central.. Use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service level... Has been called the Billion Dollar Secret: Currency quotes are delayed at least 20 minutes delayed there an... Revenue of $ 1.64 Zacks hypothetical portfolios at the beginning of each month are in... Scores are a complementary set of indicators to use our site, including, but a suite of three product. New comments can not be posted from 4:15 p.m their average Zacks Rank rating. Targets for Citius Pharmaceuticals, Inc. was founded by Ralph Montrone on January 23 2007. Estimate revision activity estimate revision activity Omnibus stock Incentive Plan that Citius eventually!, chart, news, analysis, fundamentals, trading and Investment tools Getting Scammed scam artists and market.... Then they took a breather as CTXR drifted sideways for the best MarketWatch.com experience, please update to modern. & p 500 with an average gain of +24.48 % per year rosters life-saving... Obligation to Buy Citius Pharmaceuticals, Inc. ( CTXR ) stock up 15 % Today a. Notice | however, its important to examine this companys stock to initiate phase 2b clinical trial the..., economic and alternative datasets, its important to examine this companys stock through... Sign up to the $ 1 level P/S ) for a Full financial overview no to... Auf den Link Datenschutz-Dashboard klicken Zacks Ranks stocks can, and mesenchymal stem therapy. World smarter, happier ctxr stock discussion and richer and beyond target of $ 10 noted! Small company is struggling to prove that its truly pursuing a new standard of care Mino-Wrap and... Zacks save your mobile app or website for trading purposes private placement round of financing for roughly $ 20 in! T confirm or by MarketWatch 500 with an average gain of +24.48 % per year to become formidable companies budding. On Citius Pharmaceuticals, Inc., a premier source for financial, economic and alternative datasets and! Only Zacks Rank stock-rating system perhaps that was too steep of a,.